Bepirovirsen - GSK
Alternative Names: 3228836; Bepirovirsen sodium - GSK; GSK'836; GSK-3228836B; GSK3228836; GSK3228836A; Hibsago; IONIS-HBVRx; ISIS 505358; ISIS-GSK3Rx; ISIS-HBVRxLatest Information Update: 27 Aug 2026
At a glance
- Originator Isis Pharmaceuticals
- Developer GSK
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Gene silencing; Hepatitis B surface antigen expression inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hepatitis B
Most Recent Events
- 24 Aug 2026 Registered for Hepatitis B (Treatment-experienced) in Japan (SC) - First global approval (9473570)
- 01 Jun 2026 GSK terminates phase-I/II trial in Hepatitis B (Combination therapy) in UK, Thailand, South Korea, Italy, France, Canada (SC) as a strategic decision (NCT05330455)
- 28 May 2026 Bepirovirsen receives priority review designation for Hepatitis B in China